In summary, we found that by using sensitive techniques like ASO-PCR in CD34+ cells, BCR-ABL KD mutations could be detected in almost one-third of CP-CML patients at the time of diagnosis and were found to be associated with the outcome of imatinib therapy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.